These Groundbreaking Migraine Prevention Drugs Just Smashed Clinical Trials




By Signe Dean in Science Alert.


A series of late-stage drug trials are showing great promise for a completely new generation of migraine prevention drugs, which could hit the market as early as next year.

For the millions of migraine sufferers around the world, this is the most welcome news in decades, as current treatment options are limited and no migraine-specific prevention drugs even existed – until now.

These new drugs are monoclonal antibodies – lab-made proteins of the kind that our immune system deploys to target various substances in the body. In the case of migraine, these antibodies target CGRP (calcitonin gene-related peptide), a molecule known to play a role in migraines.

Although people sometimes think of migraines as a type of bad headache, the debilitating condition actually comes with a host of symptoms including nausea, vomiting, light and noise sensitivity, and fatigue.

A migraine attack can last from a few hours to several days, and the vast majority of sufferers – over 90 percent – have episodic migraine, which means fewer than 15 days per month. Chronic migraine can be more than 15 days per month, and can have severe effects on one’s wellbeing.


To read the rest of this story, click on the link below:


Link to Migraine story

Leave a Reply

The York ME Community © 2015
Powered by Live Score & Live Score App